Nevirapine and Risk of Hepatotoxicity
Research shows that use of nevirapine for prophylaxis for two weeks or more increases rates of hepatotoxicity for individuals without HIV and HIV-positive pregnant women. Less hepatotoxicity was found in short course use of the drug, thus duration of therapy significantly predicts hepatotoxicity outcomes. This research supports the use of single dose nevirapine plus short-course nucleoside reverse transcriptase inhibitors when HAART is not available to prevent mother-to-child transmission of HIV.
Citation:
McKoy JM, Bennett CL, Scheetz MH, Differding V, Chandler KL, Scarsi KK, Yarnold PR, Sutton S, Palella F, Johnson S, Obadina E, Raisch DW, Parada JP. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf. 2009; 32(2): 147-58.
Original Article (Subscription may be required)
Abstract
Citation:
McKoy JM, Bennett CL, Scheetz MH, Differding V, Chandler KL, Scarsi KK, Yarnold PR, Sutton S, Palella F, Johnson S, Obadina E, Raisch DW, Parada JP. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf. 2009; 32(2): 147-58.
Original Article (Subscription may be required)
Abstract
